[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-ii-breast-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-ii-breast-cancer":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,82,119,152,178,208,229,257],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100480377","telehealth-resistance-exercise-intervention-to-preserve-dose-intensity-and-vitality-in-elder-breast-cancer-patients-100480377",false,"NCT05535192","TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients","TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients (THRIVE-65)","THRIVE-65","Inclusion Criteria:\n\n* Women age \\>=65\n* Diagnosed with stage I-III invasive breast cancer\n* BMI between 18-50 kg\u002Fm2\n* Scheduled to begin at least 10 weeks of neoadjuvant or adjuvant cytotoxic chemotherapy for curative intent\n* If enrolled in clinical chemotherapy drug trial, considered eligible if regimen includes an anthracycline or a taxane, unless the trial alters the chemotherapy agents\u002Fdoses according to patient response (e.g.; I-SPY trials)\n* Self-reported ability to walk for 6 minutes and\u002For 2 blocks (with or without assistive device)\n* Ability to provide written informed consent.\n* Ability to understand, speak, and read English. This is because many of the study instruments used are not readily available in multiple languages. Additionally, site-based study staff, such as exercise physiologists, are not bilingual and not all sites have access to interpreters.\n\nExclusion Criteria:\n\n* Following a therapeutic diet for co-morbid disease where the THRIVE-65 diet would be contraindicated as assessed by the RD\n* Engaging in 2 or more sessions of strength training exercise per week over a period of at least 3 consecutive months over the past year\n* Engaging in aerobic activity at a level that includes competitive events (e.g., marathon, triathlon, running races) over the past year\n* Presence of medical conditions or medications that would prohibit participation in an exercise program\n* Current use of weight-loss medication\n* Documented history of alcohol or substance abuse within the past 12 months\n* History of dementia","FEMALE","65 Years",{"count":20,"type":21},270,"ESTIMATED","INTERVENTIONAL",[24],"NA","This research is being done to assess whether an exercise intervention with protein intake support vs a health education and support program will make it easier for women age 65 or older who are receiving chemotherapy for breast cancer to receive all of their planned chemotherapy according to schedule and at the planned dose.",[27,28,29,30,31],"Breast Cancer","Stage III Breast Cancer","Breast Cancer Female","Stage I Breast Cancer","Stage II Breast Cancer",[27,28,31,30,33,34,35],"Exercise Intervention","Nutrition Intervention","Supportive Care","RECRUITING","2026-04-21",{"date":39,"type":40},"2026-04-23","ACTUAL",{"date":42,"type":40},"2023-03-20",{"date":44,"type":21},"2027-02-01",{"name":46,"class":47},"Dana-Farber Cancer Institute","OTHER",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100485016","improving-exercise-capacity-with-a-tailored-physical-activity-intervention-100485016","NCT05595577","Improving Exercise Capacity With a Tailored Physical Activity Intervention","Improving Exercise Capacity With a Tailored Physical Activity Intervention in Lymphoma and Breast Cancer Patients Undergoing Treatment","PALS","Inclusion Criteria:\n\nTo be considered eligible, participants must meet all of the following criteria:\n\n* Individuals aged 18- 85 years\n* Diagnosed with stage I-IV Hodgkin's or non-Hodgkin's lymphoma or stage I-III breast cancer\n* Expected to receive an anthracycline based chemotherapeutic regimen or other potentially cardiotoxic cancer therapies (e.g. chemotherapy regimens \\[anthracyclines, trastuzumab, rituximab\\]), immuno-therapies (immune checkpoint inhibitors \\[ICI's\\]) or radiation (within 8 weeks of completion of radiation).29-31\n* Ability to speak and understand English\n* Capacity to walk at least 2 city blocks (\\~.2 miles) on a flat surface\n* Expected survival beyond 6 months.\n* Must have an assistant that will help perform the home-based testing activities\n\nExclusion Criteria:\n\nIf the patient meets any of these criteria they are excluded from the study:\n\n* Uncontrolled hypertension (systolic blood pressure \\>190 mm Hg or diastolic blood pressure \\>100 mm Hg)\n* Recent history of alcohol or drug abuse, inflammatory conditions such as lupus or inflammatory bowel disease, or another medical condition that might compromise safety or successful completion (unless approved by the participant's physician and the Principal Investigator) NOTE: In the setting of active inflammation, participation will not be approved. If chronic disease is present and stable as judged by the participant's physician and the PI, participation will be approved.\n* Contraindications to MRI such as ferromagnetic cerebral aneurysm clips or other intracranial metal, pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices (unless approved by the participant's physician and the Principal Investigator)\n* Pregnant\n* Unstable angina\n* Contraindication for exercise training or testing\n* Inability to exercise on a treadmill or stationary cycle\n* Significant ventricular arrhythmias (\\>20 PVCs\u002Fmin due to gating difficulty)\n* Atrial fibrillation with uncontrolled ventricular response\n* Acute myocardial infarction within 28 days\n* Inability to provide informed consent","ALL","18 Years","85 Years",{"count":61,"type":21},110,[24],"The purpose of this research is to test whether participating in either a physical activity intervention or a series of educational classes will help to preserve exercise capability, heart function, brain-based activities (like memory), and quality of life.\n\nParticipants will be randomized to 1 of 2 pathways:\n\n* First pathway consists of organized health workshops. These workshops are intended to provide information on topics such as proper nutrition, management of stress, sleep practices, and emphasis on a healthy lifestyle that may help the participants through cancer treatment. This pathway will also test whether stretching may help participants through cancer treatment.\n* Second pathway participants will take part in some unsupervised and some potentially supervised moderate activity sessions each week throughout participants' cancer treatment to take place either remotely or in person, depending on availability of facilities at the time visits are scheduled.",[65,66,67,68,30,31,28],"Non Hodgkin Lymphoma","Heart; Functional Disturbance","Hodgkin Lymphoma","Quality of Life",[70,71],"Exercise capability","Brain activity","2026-03-19",{"date":74,"type":40},"2026-03-20",{"date":76,"type":40},"2023-03-01",{"date":78,"type":21},"2026-08-31",{"name":80,"class":47},"Wake Forest University Health Sciences",2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":93,"conditions":94,"keywords":102,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},"100596217","phase-4-a-study-of-revaree-plus-in-people-with-breast-cancer-100596217","NCT07042581","A Study of Revaree Plus in People With Breast Cancer","Evaluation of Revaree Plus in Women With Breast Cancer","Inclusion Criteria:\n\n* ≥18 years of age at the time of signing informed consent.\n* Stage 0-3 hormone-receptor positive breast cancer confirmed at MSKCC\n* Able to complete study questionnaires in English or Spanish\n* Breast cancer patients must have completed primary therapy (surgery, and\u002For chemotherapy, and\u002For radiation therapy) or currently on maintenance therapy\n* Currently on an aromatase inhibitor or tamoxifen or Selective Estrogen Receptor Modulators (SERM)\n* Currently have no clinical evidence of disease\n* Reporting being bothered by vaginal symptoms of estrogen deprivation (i.e., vaginal dryness, dyspareunia, or discomfort \\[pain with intercourse or examination\\])\n* A total score of 4 or greater in VAS\n* Without history of other cancers (excluding non-melanoma skin cancer)\n* Must sign an informed consent indicating that the participant understands the purpose of, and procedures required for the study and is willing to participate in the study\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Vaginal bleeding of unknown etiology within 12 months of study entry\n* Currently taking hormone replacement therapy \\[local or systemic\\] (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment)\n* Existing use of external estrogens or nonhormonal moisturizers (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment)\n* No known allergies to any ingredients in 10mg HLA suppository",{"count":90,"type":21},60,[92],"PHASE4","The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness during breast cancer treatment.",[27,95,30,31,28,96,97,98,99,100,101],"Stage 0 Breast Cancer","Stage 0 Breast Carcinoma","Stage II Breast Carcinoma","Stage III Breast Carcinoma","Hormone-receptor-positive Breast Cancer","Hormone Receptor Positive Breast Carcinoma","Hormone Receptor Positive Malignant Neoplasm of Breast",[27,95,30,31,28,103,104,105,106,107,108,109],"Stage 0 hormone receptor positive breast cancer","Stage I hormone receptor positive breast cancer","Stage II hormone receptor positive breast cancer","Stage III hormone receptor positive breast cancer","Revaree","24-374","Memorial Sloan Kettering Cancer Center","2026-02-04",{"date":112,"type":40},"2026-02-06",{"date":114,"type":40},"2025-06-20",{"date":116,"type":21},"2029-06-20",{"name":109,"class":47},7,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":57,"minAge":4,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":139,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100578450","mindfulness-based-intervention-for-depressive-symptoms-sent-via-text-mindset-100578450","NCT06811454","Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)","A Daily, Digital Mindfulness-Based Intervention for Depressive Symptoms After Serious Medical Illness","Inclusion Criteria:\n\n1. Self-reported mild to moderately-severe symptoms of depression (score 5-19 on PHQ-9).\n2. A diagnosis of stage 0-III breast, prostate, or colorectal cancer.\n3. Completion of primary cancer treatment within 2 years (excludes hormone therapy).\n4. An ability to provide informed consent.\n5. An ability to read and speak English.\n6. Access to a web-enabled device (phone, tablet, computer).\n\nExclusion Criteria:\n\n1. Self-reported minimal and severe depressive symptoms (\\\u003C4 and \\> 20 on PHQ-9).\n2. Self-reported suicidal ideation (\\>1 on item 9 PHQ-9).\n3. Another psychological, medical, or other condition\u002Fissue determined that necessitates priority treatment and\u002For that would interfere with participation (e.g., schizophrenia, borderline personality disorder)\n4. Current or recent substance abuse\u002Fdependence.\n5. Stage IV cancer diagnosis.\n6. A cancer recurrence actively requiring treatment.\n7. Self-reported active mindfulness practice.\n8. Prior participation in a formal mindfulness program (e.g., MBCT, Mindfulness-Based Stress Reduction Program, Mindfulness-Based Cancer Recovery",{"count":127,"type":21},76,[24],"The purpose of this study is to develop and test a new intervention to reduce depressive symptoms in post-treatment cancer participants.",[131,132,28,31,30,133,134,135,136,137,138],"Depression","Cancer","Stage III Prostate Cancer","Stage II Prostate Cancer","Stage I Prostate Cancer","Stage III Colorectal Cancer","Stage II Colorectal Cancer","Stage I Colorectal Cancer",[140],"Post treatment Depression","NOT_YET_RECRUITING","2026-01-22",{"date":144,"type":40},"2026-01-23",{"date":146,"type":21},"2026-08-03",{"date":148,"type":21},"2029-03-31",{"name":150,"class":47},"Case Comprehensive Cancer Center",1,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":5},"100405007","phase-2-trastuzumab-deruxtecan-alone-or-in-combination-with-anastrozole-for-the-treatment-of-early-stage-her2-low-hormone-receptor-positive-breast-cancer-100405007","NCT04553770","Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer","A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting","Inclusion Criteria:\n\n* Previously untreated operable invasive carcinoma of the breast greater than 2.0 cm (cT2) in size based on physical exam or imaging. Patients with clinical node negative disease or clinical node (cN1\u002FcN2) positive are allowed provided they are deemed to have operable disease at study entry\n* Participants with clinically involved lymph nodes should not have radiological evidence of distant disease per standard of care staging prior to patient informed consent form (PICF) signature\n* In the United States\n* Tumor is HER2-low by immunohistochemistry (IHC), defined as 1+ or 2+, confirmed by central testing (central testing results not required for enrollment, unless no local results available). If HER2 is 2+ by IHC, fluorescence in situ hybridization (FISH) must be performed (per standard of care) and the FISH result must be HER2 non-amplified per 2018 American Society of Clinical Oncology College of American Pathologists (ASCO CAP) guidelines\n* Tumor is HR positive (HR+) per ASCO CAP guidelines with known estrogen and progesterone receptor status, locally defined\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Normal cardiac function (left ventricular ejection fraction \\[LVEF\\] \\>= 50%) based on echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before randomization\u002Fenrollment\n* Platelet count \\>= 100 000\u002Fmm\\^3 (Platelet transfusion is not allowed within 1 week prior to screening assessment) (within 14 days before randomization\u002Fenrollment)\n* Hemoglobin \\>= 9.0 g\u002FdL (red blood cell transfusion is not allowed within 1 week prior to screening assessment) (within 14 days before randomization\u002Fenrollment)\n* Absolute neutrophil count (ANC) \\>=1500\u002Fmm\\^3 (Granulocyte colony-stimulating factor (G-CSF) administration is not allowed within 1 week prior to screening assessment) (within 14 days before randomization\u002Fenrollment)\n* Creatinine clearance \\>= 30 mL\u002Fmin as calculated using the Cockcroft-Gault equation or serum creatinine =\\\u003C 1.5 x upper limit of normal (ULN) (within 14 days before randomization\u002Fenrollment)\n* Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =\\\u003C 3 x ULN (within 14 days before randomization\u002Fenrollment)\n* Total bilirubin =\\\u003C 1.5 x ULN (within 14 days of randomization\u002Fenrollment). Participants with Gilbert's syndrome with a total bilirubin =\\\u003C 2.0 times ULN and direct bilirubin within normal limits are permitted\n* Serum albumin \\>= 2.5 g\u002FdL (within 14 days before randomization\u002Fenrollment)\n* International normalized ratio (INR)\u002Fprothrombin time (PT) and activated partial thromboplastin time (aPTT) =\\\u003C 1.5 x ULN (within 14 days before randomization\u002Fenrollment)\n* Has adequate treatment washout period before randomization\u002Fenrollment, defined as:\n\n  * Major surgery \\>= 4 weeks\n  * Chloroquine\u002Fhydroxychloroquine \\> 14 days\n* Negative pregnancy test (serum) for women of child bearing potential (CBP):\n\n  * Women are considered of CBP unless: they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment she is considered not of CBP\n* Male and female participants of reproductive\u002Fchildbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males after the last dose of study drug. Highly effective contraception methods include:\n\n  * Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\n  * Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks before taking trial treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment\n  * Male partner sterilization (at least 6 months prior to randomization). For female patients on the trial the vasectomized male partner should be the sole partner for that patient. If vasectomy of the male partner is the highly effective method of contraception chosen, the success of the vasectomy should be medically confirmed according to local practice\n  * Placement of an intrauterine device (IUD)\n* Male participants must not freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study drug administration. Preservation of sperm should be considered prior to enrollment in this study\n* Female participants must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration\n* Estradiol level must be in post-menopausal range per local lab interpretation prior to baseline biopsy\n\n  * Postmenopausal status is defined as:\n\n    * Patient underwent bilateral oophorectomy, or\n    * Age \\>= 60 years, or\n    * Age \\\u003C 60 years and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifene or ovarian suppression) and follicle-stimulating hormone (FSH) and plasma estradiol are in the postmenopausal ranges per local normal ranges\n  * Note: for women with therapy-induced amenorrhea, serial measurements of FSH and\u002For estradiol per local clinical guidelines are required for determination of postmenopausal status. All women who do not meet the criteria for postmenopausal status are considered premenopausal for the purpose of this trial\n* Pre- or peri-menopausal and amenable to being treated with ovarian function suppression drugs (goserelin, leuprolide, or triptorelin) per standard of care. Patients must have started treatment with ovarian function suppression at least 28 days prior to first dose of study treatment\n\nExclusion Criteria:\n\n* Recurrent or metastatic breast cancer\n* Bilateral breast cancer (multifocal or multicentric breast cancer is allowed provided that all biopsied lesions are HER2 1+ or 2+, not FISH amplified and are HR positive per ASCO guidelines)\n* Inflammatory breast cancer\n* Prior systemic therapy for invasive cancer\n\n  * Prior tamoxifen for history of ductal breast carcinoma in situ (DCIS) allowed, but no prior aromatase inhibitor, no prior chemotherapy and no prior HER2-targeted therapy\n* Prior ipsilateral chest wall radiation\n* Major surgery \\\u003C 4 weeks prior to enrollment\n* Medical history of myocardial infarction within 6 months before randomization\u002Fenrollment, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV), troponin levels consistent with myocardial infarction as defined according to the manufacturer 28 days prior to randomization\n* Unable to swallow oral medications\n* Is pregnant or lactating, or planning to become pregnant\n* Corrected QT interval prolongation to \\> 470 ms (females) or \\> 450 ms (males) based on average of the screening triplicate 12-lead electrocardiogram\n* Known hypercoaguable disorder requiring use of anticoagulant\n* Significant gastrointestinal disorders limiting absorption or tolerance of oral medications (for example, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea)\n* History of (non-infectious) interstitial lung disease (ILD)\u002Fpneumonitis that required steroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening\n* Has multiple primary malignancies within 3 years, except:\n\n  * Adequately resected non-melanoma skin cancer\n  * Curatively treated non breast in-situ disease, and other solid non-breast tumors curatively treated are allowed if \\> 3 years from diagnosis and no evidence of recurrence in that time\n  * Prior history of DCIS is allowed as long as patient has not received an aromatase inhibitor, has not received ipsilateral breast\u002Fchest radiation\n  * Prior history of contralateral invasive breast cancer (diagnosed by biopsy \\> 2 years prior to current diagnosis) is allowed provided patient has not received prior aromatase inhibitor, CDK4\u002F6 inhibitor (CDK4\u002F6i), HER2-targeted therapy or chemotherapy and has not experienced any recurrence and has no evidence of recurrence (based on standard clinical evaluation)\n* Other concurrent anti-cancer therapy. Note: ovarian function suppression drugs (goserelin, leuprolide, or triptorelin) and\u002For bone modifying agents (bisphosphonates, denosumab) do not count as anti-cancer therapy for this criteria. If taking bisphosphonates or denosumab, must have been on these agents prior to signing consent\n* Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results\n* Has known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA). Subjects should be tested for HIV prior to randomization\u002Fenrollment if required by local regulations or Institutional Review Board (IRB)\u002Fethics committee (EC)\n* Have personal history within the last 12 months of any of the following conditions: syncope of cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest\n* Have received an autologous or allogeneic stem-cell transplant\n* Has active systemic bacterial infection (requiring intravenous \\[IV\\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \\[for example, hepatitis B surface antigen positive\\]). Screening is not required for enrollment\n* Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment must be stopped prior to first baseline biopsy\n* Has history of severe hypersensitivity reactions to other monoclonal antibodies and\u002For to either the drug substances or inactive ingredients in the drug product\n* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e. pulmonary emboli within three months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease \\[COPD\\], restrictive lung disease, pleural effusion etc.), and any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (i.e. rheumatoid arthritis, Sjogren's, sarcoidosis etc.), or prior pneumonectomy\n* Life expectancy \\\u003C 3 months",{"count":160,"type":21},88,[162],"PHASE2","This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing the growth of tumors that need estrogen to grow. This study is evaluating how effective trastuzumab deruxtecan is at treating hormone receptor positive cancer cells that have low levels of HER2 expressed on them when given alone or in combination with anastrozole.",[165,100,166,31,167,168,28],"Early-stage Breast Cancer","Invasive Breast Cancer","Stage IIA Breast Cancer","Stage IIB Breast Cancer","2025-11-06",{"date":171,"type":40},"2025-11-10",{"date":173,"type":40},"2020-10-09",{"date":175,"type":21},"2026-12-31",{"name":177,"class":47},"Jonsson Comprehensive Cancer Center",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":189,"conditions":190,"keywords":193,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":48},"100522784","predicting-breast-cancer-response-to-neoadjuvant-therapy-by-ctdna-assessment-100522784","NCT06087120","Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment","Investigate the Prognostic and Predictive Value of Circulating Tumor DNA (ctDNA) During Neoadjuvant Chemotherapy for Breast Cancer.","BRAVA","Inclusion Criteria:\n\n* Female,18 years old and older,\n* Are diagnosed with stage II-III HER2+\u002FTriple Negative breast cancer and indicated for neoadjuvant chemotherapy,\n* FFPE sample is available at the time of diagnosis and operation,\n* Are voluntary to participate in the study.\n\nExclusion Criteria:\n\n* Recurrent breast cancer,\n* Other cancer metastasis to the breast,\n* Have been or are being treated for cancer,\n* Patients did not agree to participate in the studies.",{"count":187,"type":21},125,"OBSERVATIONAL","This is a prospective and observational study, aiming to determine the detection rate and change of CtDNA in blood samples of cancer patients before, during and after neoadjuvant treatment.\n\n* Determine the rate of ctDNA positivity at the time before treatment,\n* Determine the rate of ctDNA positivity at the time during treatment,\n* Determine the rate of ctDNA positivity at the time after neoadjuvant therapy, whether there is a change in ctDNA expression of the study population during treatment.\n\nAnd aiming to investigate the relationship between ctDNA expression and MRI imaging with pCR response in neo-adjuvant therapy:\n\n* Correlation between ctDNA detection and pCR response. Determine the percentage of Positive Prediction Value - PPV, Negative Prediction Value - NPV of ctDNA,\n* Correlation between MRI imaging and pCR response. Determination of PPV, NPV of MRI\n* Combination of ctDNA detection and MRI imaging in the prognosis of pCR. Determination of PPV, NPV ratio of ctDNA combined with MRI.",[29,31,28,191,192],"HER2-positive Breast Cancer","Triple Negative Breast Cancer",[194,195,196,197],"Liquid Biopsy","Circulating Tumour DNA","Vietnam","Indonesia","2025-09-18",{"date":200,"type":40},"2025-09-23",{"date":202,"type":40},"2023-09-16",{"date":204,"type":21},"2025-12-31",{"name":206,"class":207},"Gene Solutions","INDUSTRY",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":151},"100600255","a-study-of-disappearing-markers-for-daily-radiation-treatment-delivery-for-breast-cancer-patients-100600255","NCT07095114","A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.","A Phase I\u002FII Study of Disappearing Markers for Daily Radiation Treatment Delivery","Inclusion Criteria:\n\n* Participant must have histologically or cytologically confirmed stage 0 ductal carcinoma in situ (DCIS), I, II or III breast cancer and be planning to undergo radiation therapy (RT) after surgery\n* Participants must be 18 years of age or older\n* Participant must be able to understand a written informed consent document and be willing to sign it\n* Participant must be assigned female at birth\n* Participant must have a Karnofsky performance score of greater than or equal to 70%\n* Women of child bearing potential must agree to avoid becoming pregnant through defined periods during the course of RT and must meet one of the following:\n\n  * Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy\n  * Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation\n  * Agree to practice true abstinence from sexual intercourse\n  * Not in a sexual relationship in which the may become pregnant (i.e., same-sex relationship)\n  * If they are childbearing potential, agree to use at least one highly effective and at least one additional method of contraception.\n* For the first six participants only: Participant must have a Fitzpatrick Skin Tone Scale of 5 or 6\n\nExclusion Criteria:\n\n* Participants who have received prior radiation treatment to the affected breast.\n* Participants with a history of allergic reaction or hypersensitivity attributed to any tattoo ink\n* Participants with active chronic skin diseases such as psoriasis. Participants with inactive or controlled skin diseases are eligible for this study\n* Participants that are pregnant or breastfeeding. If a participant wishes to participate in this study, breastfeeding should be discontinued\n* Participants with a BMI greater than 44.5 as calculated within six months prior to the starting of the study. If there are multiple BMI measurements available in the chart, the most recent will be used to determine eligibility.",{"count":216,"type":21},30,[24],"The goal of this clinical trial is to learn if tattoos applied with Magic Ink is as safe as commercially available standard tattoo ink for the purpose of radiation in women with breast cancer undergoing radiation treatment. The main questions are:\n\n* Is the Magic Ink as safe as standard tattoo ink\n* Does Magic Ink continue to function and remain visible for radiation therapists during the treatment Participants will be consented and given a skin assessment. Once enrolled participants will be administered the Magic Ink tattoo instead of the standard tattoo ink in preparation for their radiation treatment. Participants will also complete a survey regarding body image. Skin assessment will occur again after the first week of radiation and at 3 months later. Throughout the radiation therapy the medical physicist will complete surveys about ease of set-up of the equipment.",[220,30,31,28],"Ductal Carcinoma in Situ","2025-09-12",{"date":198,"type":40},{"date":224,"type":40},"2025-08-18",{"date":226,"type":21},"2026-08-08",{"name":228,"class":47},"Barbara Ann Karmanos Cancer Institute",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":239,"conditions":240,"keywords":243,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":4},"100602874","phase-2-shr-a1811-for-her2-positive-breast-cancer-with-suboptimal-neoadjuvant-response-100602874","NCT07129187","SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response","An Open-label, Single-arm, Multicenter Study of SHR-A1811 as Neoadjuvant Therapy in HER2-positive Breast Cancer Patients With Suboptimal Neoadjuvant Response","Inclusion Criteria:\n\n* 1.Female patients with newly diagnosed breast cancer aged 18 to 70 years old;\n* 2.Early or locally advanced HER2-positive invasive breast cancer;\n* 3.Known hormone receptor status;\n* 4.ECOG score of 0-1;\n* 5.Patients who were determined by the researchers to have poor therapeutic effect after 4 cycles of neoadjuvant therapy;\n* 6.Organ function levels must meet the following requirements:\n* 7.Women of childbearing age must undergo a serum pregnancy test within 7 days before enrollment, with a negative result, and be willing to use a medically approved highly effective contraceptive method during the study and within 3 months after the last administration of the study drug.\n* 8.The subjects voluntarily participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Patients with metastatic or bilateral breast cancer, or inflammatory breast cancer\n* 2\\. Patients with grade 3 or higher thrombocytopenia during previous treatment, or grade 3 or higher nausea and vomiting despite primary prevention\n* 3\\. History of other malignant tumors (except cured carcinoma in situ of the cervix, basal cell carcinoma, etc.) and related treatment history\n* 4\\. Patients who received major non-breast cancer surgery within 4 weeks before enrollment and have not recovered (except biopsy and PICC)\n* 5\\. Autoimmune diseases (except special cases such as hypothyroidism and stable type 1 diabetes)\n* 6\\. Interstitial lung disease, non-infectious pneumonia, uncontrolled systemic diseases\n* 7\\. History of or planned administration of live attenuated vaccines within 28 days\n* 8\\. HIV infection, active hepatitis (hepatitis B, hepatitis C, etc.), autoimmune hepatitis\n* 9\\. Severe infection within 4 weeks, CTCAE grade ≥ 2 active infection within 2 weeks (except neoplastic fever), or evidence of active tuberculosis within 1 year\n* 10\\. History of allogeneic bone marrow or solid organ transplantation\n* 11\\. Peripheral neuropathy of grade ≥ 2\n* 12\\. Severe heart diseases\n* 13\\. Receipt of systemic immunostimulant therapy within 4 weeks\n* 14\\. Receipt of systemic immunosuppressant therapy within 2 weeks (except local or physiological dose of hormones)\n* 15\\. Allergy to study drugs\u002Fexcipients, or history of severe allergic reaction to other monoclonal antibodies\n* 16\\. Pregnant or lactating women; fertile women with positive pregnancy test or unwilling to take effective contraception throughout the trial\n* 17\\. History of neurological\u002Fpsychiatric disorders , or history of substance abuse, alcoholism, or drug addiction\n* 18\\. Other circumstances deemed unsuitable for enrollment by the researcher","70 Years",{"count":216,"type":21},[162],"This is an open-label, single-arm, multicenter clinical study to evaluate the efficacy and safety of SHR-A1811 in early or locally advanced HER2-positive breast cancer patients with suboptimal response to neoadjuvant regimen. Patients who were determined by the researchers to have poor therapeutic effect will switch to SHR-A1811.",[241,242,31,28],"Early Breast Cancer","HER2 + Breast Cancer",[244,245,246,247],"neoadjuvant therapy","antibody drug conjugate","SHR-A1811","suboptimal response","2025-08-20",{"date":250,"type":40},"2025-08-26",{"date":252,"type":21},"2025-10",{"date":254,"type":21},"2030-10",{"name":256,"class":47},"Chuan Wang",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":236,"enrollmentInfo":265,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":266,"conditions":267,"keywords":268,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":151},"100503315","comparison-between-prepectoral-and-subpectoral-breast-reconstruction-100503315","NCT05833659","Comparison Between Prepectoral and Subpectoral Breast Reconstruction","The Comparison Between Prepectoral Breast Reconstruction and Subpectoral Breast Reconstruction Following Single-port Insufflation Endoscopic Nipple-sparing Mastectomy","RESPECT","Inclusion Criteria:\n\n1. Female patients with preoperative pathologically confirmed early-stage invasive breast cancer (stage I or stage II) by core needle biopsy.\n2. Breast-conserving surgery is not possible due to the presence of contraindications to breast-conserving surgery, or the patient actively requests total mastectomy.\n3. Patients having willingness for breast reconstruction.\n4. Age between 18 to 70 years.\n5. Maximum diameter of the cancer lesion ≤ 3 cm.\n6. Physical examination and breast magnetic resonance imaging (MRI) confirmed that the tumor did not invade the skin, subcutaneous tissue, or chest wall.\n7. The distance between the lesion and the nipple is ≥2 cm, and it is confirmed by physical examination and MRI that the nipple-areola complex is not invaded.\n8. Eastern Cooperative Oncology Group (ECOG) Performance Status Scale of 0 to 2.\n\nExclusion Criteria:\n\n1. patients having serious medical diseases, including unstable angina pectoris, myocardial infarction, and cerebrovascular accident within 6 months.\n2. Having history of malignant tumor (s) within 5 years.\n3. Patients under immunosuppressive therapy for organ transplantation.\n4. Having continuous systemic steroid hormone therapy.\n5. Pregnant or lactating women.",{"count":160,"type":21},"There are controversies about breast implant-based reconstruction techniques. Our center pioneered single-port insufflation endoscopic nipple-sparing mastectomy (SIE-NSM) combined with stage I prosthesis reconstruction. The study's primary objective is to compare single-port endoscopic NSM combined with pre-pectoral breast reconstruction to the subpectoral breast reconstruction group regarding breast satisfaction.\n\nThis study is an ambispective cohort study. The study will be conducted at Beijing Friendship Hospital, affiliated with Capital Medical University. Patients will be enrolled retrospectively from January 2014 to March 2022 by reviewing the medical records and recruited prospectively from March 2022 to March 2025. The two cohorts are the pre-pectoral breast reconstruction cohort and the subpectoral breast reconstruction cohort, both following single-port insufflation endoscopic nipple-sparing mastectomy. The primary outcome of this study is postoperative breast satisfaction, which the BREAST-Q score will measure. The different variables will be compared using the Χ2 test for categorical variables and the Mann-Whitney test for continuous variables.",[31,30],[269,270,271,272,273],"breast cancer","endoscopic nipple-sparing mastectomy","breast reconstruction","breast satisfaction","BREAST-Q score","2023-04-16",{"date":276,"type":40},"2023-04-27",{"date":278,"type":40},"2022-03-01",{"date":280,"type":21},"2027-03",{"name":282,"class":47},"Beijing Friendship Hospital"]